GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (WBO:NZYM) » Definitions » Cyclically Adjusted Revenue per Share

Novonesis (Novozymes) B (WBO:NZYM) Cyclically Adjusted Revenue per Share : €8.35 (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Novonesis (Novozymes) B Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Novonesis (Novozymes) B's adjusted revenue per share for the three months ended in Dec. 2024 was €4.386. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €8.35 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Novonesis (Novozymes) B's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Novonesis (Novozymes) B was 9.20% per year. The lowest was 4.40% per year. And the median was 8.10% per year.

As of today (2025-05-10), Novonesis (Novozymes) B's current stock price is €59.58. Novonesis (Novozymes) B's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 was €8.35. Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio of today is 7.14.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Novonesis (Novozymes) B was 11.43. The lowest was 5.01. And the median was 7.82.


Novonesis (Novozymes) B Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Novonesis (Novozymes) B's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B Cyclically Adjusted Revenue per Share Chart

Novonesis (Novozymes) B Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.03 6.46 7.30 7.82 8.35

Novonesis (Novozymes) B Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Dec24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.48 7.61 7.82 8.01 8.35

Competitive Comparison of Novonesis (Novozymes) B's Cyclically Adjusted Revenue per Share

For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio falls into.


;
;

Novonesis (Novozymes) B Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novonesis (Novozymes) B's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=4.386/118.9000*118.9000
=4.386

Current CPI (Dec. 2024) = 118.9000.

Novonesis (Novozymes) B Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201409 1.361 99.700 1.623
201412 1.368 99.400 1.636
201503 1.541 100.200 1.829
201506 1.489 100.300 1.765
201509 1.528 100.200 1.813
201512 1.503 99.800 1.791
201603 1.582 100.200 1.877
201606 1.514 100.600 1.789
201609 1.504 100.200 1.785
201612 1.682 100.300 1.994
201703 1.681 101.200 1.975
201706 1.597 101.200 1.876
201709 1.629 101.800 1.903
201712 1.653 101.300 1.940
201803 1.601 101.700 1.872
201806 1.602 102.300 1.862
201809 1.678 102.400 1.948
201812 1.717 102.100 2.000
201903 1.613 102.900 1.864
201906 1.608 102.900 1.858
201909 1.736 102.900 2.006
201912 1.758 102.900 2.031
202003 1.789 103.300 2.059
202006 1.590 103.200 1.832
202009 1.637 103.500 1.881
202012 1.652 103.400 1.900
202103 1.807 104.300 2.060
202106 1.715 105.000 1.942
202109 1.808 105.800 2.032
202112 1.841 106.600 2.053
202203 2.103 109.900 2.275
202206 2.062 113.600 2.158
202209 2.109 116.400 2.154
202212 2.175 115.900 2.231
202303 2.234 117.300 2.264
202306 2.038 116.400 2.082
202309 2.147 117.400 2.174
202312 4.377 116.700 4.460
202406 0.000 118.500 0.000
202412 4.386 118.900 4.386

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Novonesis (Novozymes) B  (WBO:NZYM) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=59.58/8.35
=7.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Novonesis (Novozymes) B was 11.43. The lowest was 5.01. And the median was 7.82.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Novonesis (Novozymes) B Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Novonesis (Novozymes) B's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Novonesis (Novozymes) B Business Description

Industry
Address
Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.

Novonesis (Novozymes) B Headlines

No Headlines